Header Logo

Connection

Patrick Arbuthnot to Virus Replication

Back to Details
This is a "connection" page, showing publications Patrick Arbuthnot has written about Virus Replication.
Patrick Arbuthnot
Connection Strength
7,812
Virus Replication
  1. Inhibition of replication of hepatitis B virus using transcriptional repressors that target the viral DNA. BMC Infect Dis. 2019 Sep 12; 19(1):802.
    View in: PubMed
    Score: 0,637
  2. Sustained inhibition of hepatitis B virus replication in vivo using RNAi-activating lentiviruses. Gene Ther. 2015 Feb; 22(2):163-71.
    View in: PubMed
    Score: 0,454
  3. Inhibition of hepatitis B virus replication by helper dependent adenoviral vectors expressing artificial anti-HBV pri-miRs from a liver-specific promoter. Biomed Res Int. 2014; 2014:718743.
    View in: PubMed
    Score: 0,442
  4. Inhibition of HBV replication in vivo using helper-dependent adenovirus vectors to deliver antiviral RNA interference expression cassettes. Antivir Ther. 2014; 19(4):363-73.
    View in: PubMed
    Score: 0,427
  5. Inactivation of hepatitis B virus replication in cultured cells and in vivo with engineered transcription activator-like effector nucleases. Mol Ther. 2013 Oct; 21(10):1889-97.
    View in: PubMed
    Score: 0,416
  6. Inhibition of hepatitis B virus replication in cultured cells and in vivo using 2'-O-guanidinopropyl modified siRNAs. Bioorg Med Chem. 2013 Oct 15; 21(20):6145-55.
    View in: PubMed
    Score: 0,410
  7. Efficient silencing of hepatitis B virus by helper-dependent adenovirus vector-mediated delivery of artificial antiviral primary micro RNAs. Microrna. 2012; 1(1):19-25.
    View in: PubMed
    Score: 0,374
  8. Countering hepatitis B virus infection using RNAi: how far are we from the clinic? Rev Med Virol. 2011 Nov; 21(6):383-96.
    View in: PubMed
    Score: 0,366
  9. Inhibition of hepatitis B virus replication with linear DNA sequences expressing antiviral micro-RNA shuttles. Biochem Biophys Res Commun. 2009 Nov 20; 389(3):484-9.
    View in: PubMed
    Score: 0,318
  10. Efficient inhibition of hepatitis B virus replication in vivo, using polyethylene glycol-modified adenovirus vectors. Hum Gene Ther. 2008 Nov; 19(11):1325-31.
    View in: PubMed
    Score: 0,300
  11. Expressed anti-HBV primary microRNA shuttles inhibit viral replication efficiently in vitro and in vivo. Mol Ther. 2008 Jun; 16(6):1105-12.
    View in: PubMed
    Score: 0,289
  12. Specific inhibition of HBV replication in vitro and in vivo with expressed long hairpin RNA. Mol Ther. 2007 Mar; 15(3):534-41.
    View in: PubMed
    Score: 0,265
  13. Effective anti-hepatitis B virus hammerhead ribozymes derived from multimeric precursors. Oligonucleotides. 2007; 17(1):104-12.
    View in: PubMed
    Score: 0,264
  14. Effective inhibition of HBV replication in vivo by anti-HBx short hairpin RNAs. Mol Ther. 2006 Feb; 13(2):411-21.
    View in: PubMed
    Score: 0,245
  15. Exploiting the RNA interference pathway to counter hepatitis B virus replication. Liver Int. 2005 Feb; 25(1):9-15.
    View in: PubMed
    Score: 0,231
  16. In Vivo Modelling of Hepatitis B Virus Subgenotype A1 Replication Using Adeno-Associated Viral Vectors. Viruses. 2021 11 09; 13(11).
    View in: PubMed
    Score: 0,185
  17. Hepatitis B virus: promising drug targets and therapeutic implications. Expert Opin Ther Targets. 2021 06; 25(6):451-466.
    View in: PubMed
    Score: 0,178
  18. Advances with RNAi-Based Therapy for Hepatitis B Virus Infection. Viruses. 2020 08 04; 12(8).
    View in: PubMed
    Score: 0,169
  19. Recent developments with advancing gene therapy to treat chronic infection with hepatitis B virus. Curr Opin HIV AIDS. 2020 05; 15(3):200-207.
    View in: PubMed
    Score: 0,166
  20. Generating DNA Expression Cassettes Encoding Multimeric Artificial MicroRNA Precursors. Methods Mol Biol. 2020; 2115:185-197.
    View in: PubMed
    Score: 0,163
  21. ssAAVs containing cassettes encoding SaCas9 and guides targeting hepatitis B virus inactivate replication of the virus in cultured cells. Sci Rep. 2017 08 07; 7(1):7401.
    View in: PubMed
    Score: 0,138
  22. Advances with using CRISPR/Cas-mediated gene editing to treat infections with hepatitis B virus and hepatitis C virus. Virus Res. 2018 01 15; 244:311-320.
    View in: PubMed
    Score: 0,132
  23. Activating the innate immune response to counter chronic hepatitis B virus infection. Expert Opin Biol Ther. 2016 12; 16(12):1517-1527.
    View in: PubMed
    Score: 0,130
  24. Progress With Developing Use of Gene Editing To Cure Chronic Infection With Hepatitis B Virus. Mol Ther. 2016 Apr; 24(4):671-7.
    View in: PubMed
    Score: 0,125
  25. Differing prospects for the future of using gene therapy to treat infections with hepatitis B virus and hepatitis C virus. Discov Med. 2015 Sep; 20(109):137-43.
    View in: PubMed
    Score: 0,120
  26. Progress and Prospects of Anti-HBV Gene Therapy Development. Int J Mol Sci. 2015 Jul 31; 16(8):17589-610.
    View in: PubMed
    Score: 0,120
  27. Inhibition of replication of hepatitis B virus in transgenic mice following administration of hepatotropic lipoplexes containing guanidinopropyl-modified siRNAs. J Control Release. 2015 Jul 10; 209:198-206.
    View in: PubMed
    Score: 0,118
  28. Impact of sustained RNAi-mediated suppression of cellular cofactor Tat-SF1 on HIV-1 replication in CD4+ T cells. Virol J. 2012 Nov 15; 9:272.
    View in: PubMed
    Score: 0,099
  29. tRNA Lys3 promoter cassettes that efficiently express RNAi-activating antihepatitis B virus short hairpin RNAs. Biochem Biophys Res Commun. 2010 Aug 06; 398(4):640-6.
    View in: PubMed
    Score: 0,084
  30. Efficient silencing of gene expression with modular trimeric Pol II expression cassettes comprising microRNA shuttles. Nucleic Acids Res. 2009 Jul; 37(13):e91.
    View in: PubMed
    Score: 0,078
  31. Controlling HBV replication in vivo by intravenous administration of triggered PEGylated siRNA-nanoparticles. Mol Pharm. 2009 May-Jun; 6(3):706-17.
    View in: PubMed
    Score: 0,078
  32. Silencing of HIV-1 subtype C primary isolates by expressed small hairpin RNAs targeted to gag. AIDS Res Hum Retroviruses. 2006 May; 22(5):401-10.
    View in: PubMed
    Score: 0,063
  33. Regulatory elements of hepatitis B virus transcription. J Viral Hepat. 2002 Sep; 9(5):323-31.
    View in: PubMed
    Score: 0,049
  34. Advances in designing Adeno-associated viral vectors for development of anti-HBV gene therapeutics. Virol J. 2021 12 13; 18(1):247.
    View in: PubMed
    Score: 0,047
  35. Improved Specificity and Safety of Anti-Hepatitis B Virus TALENs Using Obligate Heterodimeric FokI Nuclease Domains. Viruses. 2021 07 12; 13(7).
    View in: PubMed
    Score: 0,045
  36. Silencing hepatitis B virus covalently closed circular DNA: The potential of an epigenetic therapy approach. World J Gastroenterol. 2021 Jun 21; 27(23):3182-3207.
    View in: PubMed
    Score: 0,045
  37. Pathogenic effects of Rift Valley fever virus NSs gene are alleviated in cultured cells by expressed antiviral short hairpin RNAs. Antivir Ther. 2012; 17(4):643-56.
    View in: PubMed
    Score: 0,024
  38. The efficacy of generating three independent anti-HIV-1 siRNAs from a single U6 RNA Pol III-expressed long hairpin RNA. PLoS One. 2008 Jul 02; 3(7):e2602.
    View in: PubMed
    Score: 0,018
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.